Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity

Toxicological Sciences

Volumn 132, Issue 2, 2013, Pages 317-326

  Pointon, Amy ^a   Abi gerges, Najah ^a   Cross, Michael J ^b   Sidaway, James E ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Cardiotoxicity; Drug discovery and development; HESC CMs; In vitro

Indexed keywords

CALCIUM ION; CARDIOTOXIN;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; DOG; ENDOPLASMIC RETICULUM; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMBRANE PERMEABILITY; NONHUMAN; PHENOTYPE; PROTEIN STRUCTURE; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOTOXINS; CELL LINE; CELL MEMBRANE PERMEABILITY; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; RATS;

EID: 84875237101     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft005     Document Type: Article

References (55)

1. Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R., Bohlen, H., Ehlich, A., Kolossov, E., et al. (2012). Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br. J. Pharmacol. 165, 1424-144
2. Abi-Gerges, N., Valentin, J. P., and Pollard, C. E. (2010). Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: Short-term variability and proarrhythmic potential. Br. J. Pharmacol. 159, 77-9
3. Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., and Noonan, D. M. (2010). Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J. Natl. Cancer Inst. 102, 14-2
4. Altschafl, B. A., Arvanitis, D. A., Fuentes, O., Yuan, Q., Kranias, E. G., and Valdivia, H. H. (2011). Dual role of junctin in the regulation of ryanodine receptors and calcium release in cardiac ventricular myocytes. J. Physiol. (Lond.) 589(Pt 24), 6063-608
5. Arai, M., Tomaru, K., Takizawa, T., Sekiguchi, K., Yokoyama, T., Suzuki, T., and Nagai, R. (1998). Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J. Mol. Cell. Cardiol. 30, 243-25
6. Bers, D. M. (2002). Cardiac excitation-contraction coupling. Nature 415, 198-20
7. Berthiaume, J. M., and Wallace, K. B. (2007). Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23, 15-2
8. Bocci, G., Danesi, R., Di Paolo, A. D., Innocenti, F., Allegrini, G., Falcone, A., Melosi, A., Battistoni, M., Barsanti, G., Conte, P. F., et al. (2000). Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin. Cancer Res. 6, 3032-303
9. Caspi, O., Itzhaki, I., Kehat, I., Gepstein, A., Arbel, G., Huber, I., Satin, J., and Gepstein, L. (2009). In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 18, 161-17
10. Claycomb, W. C., Lanson, N. A. Jr, Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A., and Izzo, N. J. Jr. (1998). HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U.S.A. 95, 2979-298
11. Conway, S. J., and Koushik, S. V. (2001). Cardiac sodium-calcium exchanger: A double-edged sword. Cardiovasc. Res. 51, 194-19
12. 2+ transient of failing human ventricular myocytes. Circ. Res. 84, 435-44
13. Duchen, M. R. (2004). Roles of mitochondria in health and disease. Diabetes 53(Suppl 1), S96-10
14. Dykens, J. A., and Will, Y. (2007). The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 12, 777-78
15. Force, T., and Kolaja, K. L. (2011). Cardiotoxicity of kinase inhibitors: The prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10, 111-12
16. Force, T., Krause, D. S., and Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332-34
17. Gao, J., Xiong, Y., Ho, Y. S., Liu, X., Chua, C. C., Xu, X., Wang, H., Hamdy, R., and Chua, B. H. (2008). Glutathione peroxidase 1-deficient mice are more susceptible to doxorubicin-induced cardiotoxicity. Biochim. Biophys. Acta 1783, 2020-202
18. Genschow, E., Spielmann, H., Scholz, G., Seiler, A., Brown, N., Piersma, A., Brady, M., Clemann, N., Huuskonen, H., Paillard, F., et al. (2002). The ECVAM international validation study on in vitro embryotoxicity tests: Results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern. Lab. Anim. 30, 151-17
19. Gerencser, A. A., Chinopoulos, C., Birket, M. J., Jastroch, M., Vitelli, C., Nicholls, D. G., and Brand, M. D. (2012). Quantitative measurement of mitochondrial membrane potential in cultured cells: Calcium-induced deand hyperpolarization of neuronal mitochondria. J. Physiol. (Lond.) 590(Pt 12), 2845-287
20. Guo, L., Abrams, R., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., and Kolaja, K. L. (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell derived cardiomyocytes. Toxicol. Sci. 123, 281-28
21. Gwathmey, J. K., Tsaioun, K., and Hajjar, R. J. (2009). Cardionomics: A new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin. Drug Metab. Toxicol. 5, 647-66
22. Harmer, A. R., Abi-Gerges, N., Morton, M. J., Pullen, G. F., Valentin, J. P., and Pollard, C. E. (2012). Validation of an in vitro contractility assay using canine ventricular myocytes. Toxicol. Appl. Pharmacol. 260, 162-17
23. Hasinoff, B. B. (2010). The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol. Appl. Pharmacol. 244, 190-19
24. Heath-Engel, H. M., and Shore, G. C. (2006). Mitochondrial membrane dynamics, cristae remodelling and apoptosis. Biochim. Biophys. Acta 1763, 549-56
25. Hescheler, J., Meyer, R., Plant, S., Krautwurst, D., Rosenthal, W., and Schultz, G. (1991). Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ. Res. 69, 1476-148
26. Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J., and Kroemer, G. (2011). Cell death assays for drug discovery. Nat. Rev. Drug Discov. 10, 221-23
27. Kerkela, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908-91
28. Kerkela, R., Woulfe, K. C., Durand, J. B., Vagnozzi, R., Kramer, D., Chu, T. F., Beahm, C., Chen, M. H., and Force, T. (2009). Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2, 15-2
29. Kimes, B. W., and Brandt, B. L. (1976). Properties of a clonal muscle cell line from rat heart. Exp. Cell Res. 98, 367-38
30. Laposa, R. R. (2011). Stem cells for drug screening. J. Cardiovasc. Pharmacol. 58, 240-24
31. Lasko, T. A., Bhagwat, J. G., Zou, K. H., and Ohno-Machado, L. (2005). The use of receiver operating characteristic curves in biomedical informatics. J. Biomed. Inform. 38, 404-41
32. Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 163, 675-69
33. Lax, A., Soler, F., and Fernández-Belda, F. (2009). Mitochondrial damage as death inducer in heart-derived H9c2 cells: More than one way for an early demise. J. Bioenerg. Biomembr. 41, 369-37
34. 2+ signaling via the sarcoplasmic reticulum-mitochondrion interface during hypoxia/reoxygenation. J. Biomed. Sci. 17, 5
35. Mattiello, J. A., Margulies, K. B., Jeevanandam, V., and Houser, S. R. (1998). Contribution of reverse-mode sodium-calcium exchange to contractions in failing human left ventricular myocytes. Cardiovasc. Res. 37, 424-43
36. Mellor, H. R., Bell, A. R., Valentin, J. P., and Roberts, R. R. (2011). Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. 120, 14-3
37. Minamino, T., and Kitakaze, M. (2010). ER stress in cardiovascular disease. J. Mol. Cell. Cardiol. 48, 1105-111
38. Murphy, C. A., and Dargie, H. J. (2007). Drug-induced cardiovascular disorders. Drug Saf. 30, 783-80
39. O'Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006). High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80, 580-60
40. Pollard, C. E., Abi Gerges, N., Bridgland-Taylor, M. H., Easter, A., Hammond, T. G., and Valentin, J. P. (2010). An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br. J. Pharmacol. 159, 12-2
41. 2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants. Toxicol. In Vitro 24, 960-97
42. Regula, K. M., and Kirshenbaum, L. A. (2005). Apoptosis of ventricular myocytes: A means to an end. J. Mol. Cell. Cardiol. 38, 3-1
43. Rolletschek, A., Blyszczuk, P., and Wobus, A. M. (2004). Embryonic stem cellderived cardiac, neuronal and pancreatic cells as model systems to study toxicological effects. Toxicol. Lett. 149, 361-36
44. Rostagno, C., Domenichetti, S., Pastorelli, F., and Gensini, G. F. (2011). Usefulness of NT-pro-BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity. J. Clin. Psychopharmacol. 31, 712-71
45. Schimmel, K. J., Richel, D. J., van den Brink, R. B., and Guchelaar, H. J. (2004). Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev. 30, 181-19
46. Spielmann, H., Seiler, A., Bremer, S., Hareng, L., Hartung, T., Ahr, H., Faustman, E., Haas, U., Moffat, G. J., Nau, H., et al. (2006). The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). Altern. Lab. Anim. 34, 527-53
47. Thomas, C. E., and Will, Y. (2012). The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery. Expert Opin. Drug Discov. 7, 109-12
48. Tokarska-Schlattner, M., Wallimann, T., and Schlattner, U. (2002). Multiple interference of anthracyclines with mitochondrial creatine kinases: Preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol. Pharmacol. 61, 516-52
49. Valentin, J. P., Bialecki, R., Ewart, L., Hammond, T., Leishmann, D., Lindgren, S., Martinez, V., Pollard, C., Redfern, W., and Wallis, R. (2009). A framework to assess the translation of safety pharmacology data to humans. J. Pharmacol. Toxicol. Methods 60, 152-15
50. Valentin, J. P., Pollard, C., Lainée, P., and Hammond, T. (2010). Value of nonclinical cardiac repolarization assays in supporting the discovery and development of safer medicines. Br. J. Pharmacol. 159, 25-3
51. Wallace, K. B. (2007). Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc. Toxicol. 7, 101-10
52. White, S. M., Constantin, P. E., and Claycomb, W. C. (2004). Cardiac physiology at the cellular level: Use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am. J. Physiol. Heart Circ. Physiol. 286, H823-H82
53. Will, Y., Dykens, J. A., Nadanaciva, S., Hirakawa, B., Jamieson, J., Marroquin, L. D., Hynes, J., Patyna, S., and Jessen, B. A. (2008). Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol. Sci. 106, 153-16
54. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97-10
55. Zeevi-Levin, N., Itskovitz-Eldor, J., and Binah, O. (2012). Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacol. Ther. 134, 180-18